Adipose-Derived Mesenchymal Stem Cells, Autologous Adipose Stromal Vascular Fraction, Mesenchymal Stem Cells, Venous Leg Ulcer
Conditions
Keywords
Cytori Celution System
Brief summary
To evaluate the efficacy and safety of Cytori Celution System in Hungarian patients with chronic non-healing venous leg ulcers.
Detailed description
This motive trial can help to establish routine application of this internationally widely used device at University of Szeged. The primary outcome is the reduction rate of the wound size. The treatment response will be calculated from wound size before and after treatment. Any adverse events related to the study device will be monitored.
Interventions
DEVICEVenous leg ulcer treatment with adipous SVF
The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
Sponsors
Szeged University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent 2. Males or females age ≥ 18 3. At least one venous chronic leg ulcer with the following condition 3.1. Ulcer is present beyond 2 months 3.2. Conservative treatment not leading to improvement 3.3. Wound size between ≥5 and ≤100 cm2 4. Ability to safely undergo tissue harvest that is anticipated to yield \>100mL of adipose tissue at a site that is free from infection and injury 5. Able and willing to work with the doctor, adhere to therapeutic prescriptions and appear on prescribed examinations 6. Normal or clinically not significant abnormal values based on investigator judgement on white blood cell count (WBC), C-reactive protein (CRP), Platelets, international normalized ratio (INR), partial thromboplastin time (APTT), haemoglobin (Hgb), Renal and Liver function 7. Females of childbearing potential must have a negative pregnancy test at the Screen Visit 8. Females of childbearing potential must agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which has a proven low failure rate of less than 1%
Exclusion criteria
1. More than 20% change in surface area of target ulcer between screening and enrollment visit. 2. There is bone involvement in case of ulcer 3. Patient with a history of bleeding disorder 4. Therapy for anticoagulation 5. Patient receiving corticosteroids, immunosuppressive or cytotoxic agents, and all systemic agents that can affect wound repair 6. Patient with any treatment that might interfere with the assessment of the study treatment 7. Pregnant or likely to become pregnant or lactating women 8. Participation in any type of clinical investigation concurrently or in the last 6 months 9. Positive for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) and syphilis (results within 1 month are acceptable) 10. Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for the participation in the study. 11. Active cancer during chemotherapy or radiotherapy, or recent cancer, if the remission had place less than 5 years before joining the study (except basal cell skin cancer) 12. Patient currently undergoing dialysis for renal insufficiency (serum creatinine ≥2 mg/dL) 13. In the opinion of treating physician, patient not expected to survive beyond 30 days 14. Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance 15. Uncontrolled chronic disease 16. Patient with history of severe alcohol or drug abuse 17. Lack of patient's cooperation 18. Use with blood thinners within 8 weeks of enrollment 19. Systemic treatments with a possible effect on ulcers within 4 weeks prior to enrollment with the following exceptions: 1. Ustekinumab (within 16 weeks prior to enrollment) 2. Adalimumab, infliximab, alefacept (within 8 weeks prior to enrollment)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction rate of the wound size | 28 days | The treatment response will be calculated from wound size before and after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Wound closure at Day 28 | 28 days | Percentage of patients achieving 50% wound closure at Day 28 |
| Improvement of Quality of Life (QoL) - EQ-5D-5L | 28 days | The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. |
| Improvement Wound pain | 28 days | Improvement Wound pain visual analogue scale (VAS) |
Countries
Hungary
Contacts
Primary ContactBalázs Bende
Outcome results
None listed